A new plasma biomarker approach is aiming to connect amyloid biology with synuclein-driven neurodegeneration. In npj Parkinson’s Disease, researchers identified plasma phosphorylated tau 217 (p-tau217) as a sensitive indicator of amyloid-β accumulation in neuronal synuclein diseases. If validated across broader patient cohorts, a blood-based marker like p-tau217 could support faster diagnosis and longitudinal monitoring without relying on more invasive or specialized assessments. For neurodegeneration drug development, biomarkers that map onto key pathologies can also help refine trial enrichment and clinical endpoints. The reported work adds to the push for measurable, disease-relevant signals that can move from research settings into scalable clinical workflows.